The International Journal of Biostatistics
Ed. by Chambaz, Antoine / Hubbard, Alan E. / van der Laan, Mark J.
2 Issues per year
IMPACT FACTOR 2013: 0.948
SCImago Journal Rank (SJR): 1.039
Source Normalized Impact per Paper (SNIP): 0.746
Mathematical Citation Quotient 2013: 0.04
Volume 11 (2015)
Volume 7 (2011)
Volume 5 (2009)
Volume 4 (2008)
Volume 3 (2007)
Volume 2 (2006)
Volume 1 (2005)
Most Downloaded Articles
- An Introduction to Causal Inference by Pearl, Judea
- Sample Size Estimation for Repeated Measures Analysis in Randomized Clinical Trials with Missing Data by Lu, Kaifeng/ Luo, Xiaohui and Chen, Pei-Yun
- Survival Models in Health Economic Evaluations: Balancing Fit and Parsimony to Improve Prediction by Jackson, Christopher H/ Sharples, Linda D and Thompson, Simon G
- Accuracy of Conventional and Marginal Structural Cox Model Estimators: A Simulation Study by Xiao, Yongling/ Abrahamowicz, Michal and Moodie, Erica E. M.
- Evaluating treatment effectiveness in patient subgroups: a comparison of propensity score methods with an automated matching approach by Radice, Rosalba/ Ramsahai, Roland/ Grieve, Richard/ Kreif, Noemi/ Sadique, Zia and Sekhon, Jasjeet S.
Commentary on "Principal Stratification -- a Goal or a Tool?" by Judea Pearl
1Fred Hutchinson Cancer Research Center & University of Washington
2University of North Carolina at Chapel Hill
3University of Minnesota, Twin Cities
Citation Information: The International Journal of Biostatistics. Volume 7, Issue 1, Pages 1–15, ISSN (Online) 1557-4679, DOI: 10.2202/1557-4679.1341, September 2011
- Published Online:
This commentary takes up Pearl's welcome challenge to clearly articulate the scientific value of principal stratification estimands that we and colleagues have investigated, in the area of randomized placebo-controlled preventive vaccine efficacy trials, especially trials of HIV vaccines. After briefly arguing that certain principal stratification estimands for studying vaccine effects on post-infection outcomes are of genuine scientific interest, the bulk of our commentary argues that the “causal effect predictiveness” (CEP) principal stratification estimand for evaluating immune biomarkers as surrogate endpoints is not of ultimate scientific interest, because it evaluates surrogacy restricted to the setting of a particular vaccine efficacy trial, but is nevertheless useful for guiding the selection of primary immune biomarker endpoints in Phase I/II vaccine trials and for facilitating assessment of transportability/bridging surrogacy.